Invasive Pneumococcal Disease in Massachusetts Children 6 Years Following Introduction of PCV13
Yildirim I, Little B, Pelton S. Invasive Pneumococcal Disease in Massachusetts Children 6 Years Following Introduction of PCV13. Open Forum Infectious Diseases 2017, 4: s67-s67. DOI: 10.1093/ofid/ofx162.159.Peer-Reviewed Original ResearchInvasive pneumococcal diseaseYears of ageNonvaccine serotypesSpeaker honorariaStreptococcus pneumoniaePneumococcal diseaseVaccine serotypesIncidence of IPDImplementation of PCV13Common clinical presentationIntroduction of PCV13Overall mortality rateChildhood immunization scheduleChildren 6 yearsProportion of casesMA childrenEnhanced surveillance systemIPD incidenceMerck vaccineIPD casesConjugate vaccinePCV13 eraClinical presentationComorbid conditionsImmunization scheduleImpact of PCV13 on Serotype 3 Invasive Pneumococcal Disease and Nasopharyngeal Carriage in Massachusetts’ Children
Lapidot R, Shea K, Little B, Yildirim I, Pelton S. Impact of PCV13 on Serotype 3 Invasive Pneumococcal Disease and Nasopharyngeal Carriage in Massachusetts’ Children. Open Forum Infectious Diseases 2017, 4: s467-s467. PMCID: PMC5631065, DOI: 10.1093/ofid/ofx163.1194.Peer-Reviewed Original ResearchPresence of comorbiditiesIPD casesPCV13 implementationYears of ageClinical syndromeSpeaker honorariaNP carriageNasopharyngeal carriageSerotype 3 invasive pneumococcal diseaseInvasive pneumococcal disease incidenceAge distributionEffectiveness of PCV13Impact of PCV13US census estimatesInvasive pneumococcal diseasePneumococcal disease incidenceAnnual incidence rateActive Surveillance NetworkAnnual prevalence rateIPD incidenceMerck vaccinePCV13 dosePneumococcal diseaseVaccination statusVaccine serotypes